Table 2.
Incidence of events according to quartiles of sVEGFR‐2
| Event | Entire cohort | Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 |
|---|---|---|---|---|---|
| CV death | 113 (11.0) | 41 (16.0) | 28 (10.9) | 25 (9.8) | 19 (7.4) |
| All‐cause death | 211 (20.6) | 72 (28.1) | 50 (19.5) | 49 (19.1) | 40 (15.6) |
| MACE (CV death + HF hospitalization) | 350 (34.2) | 94 (36.7) | 85 (33.2) | 85 (33.2) | 86 (33.6) |
| HF hospitalization | 309 (30.2) | 77 (30.1) | 74 (28.9) | 77 (30.1) | 81 (31.6) |
Variables are presented as numbers (percentages).
CV, cardiovascular; HF, heart failure; MACE, major adverse cardiovascular events defined as a composite of CV death and HF‐related hospitalization; sVEGFR‐2, soluble vascular endothelial growth factor receptor 2.